Industry news

New PhRMA Report: Nearly 200 medicines in development for heart disease, stroke and other cardiovascular diseases

Ieva M. Augstums / PhRMA

With more than 85 million Americans living with some type of cardiovascular disease, including more than six million adults who have had a stroke, chances are that you or someone you know would stand to benefit from new medicines that help prevent and treat these illnesses.

Exits boost PE fund return multiples; VC vintages with potential to be realized

PitchBook Blog

Powered by data from the PitchBook Platform and sponsored by R.R. Donnelley, our 4Q 2015 PE & VC Benchmarking Report examines more than a decade of global fund performance, utilizing metrics such as IRRs, fund return multiples and fund cash flows.

Analyst: Use of tech to streamline clinical trials 'still early in its adoption cycle'

Nick Paul Taylor / Fierce Biotech IT

In recent years, technology has gone from being a novelty in clinical trials to the cornerstone of the research process. But with sponsors and CROs alike looking to IT to make studies more efficient, the expectation among observers is that the incorporation of tech into trials is just getting started.

Pharma brands need the human touch, and MS marketing offers some ideas

Carly Helfand / FiercePharmaMarketing

What's the best path forward for healthcare brands? It starts with making a difference and serving the people they're working to connect with, according to Digitas Health executive director Graham Mills--and that's something he says marketers in the multiple sclerosis space already do exceptionally well.

Developer of simple, procedural solution to sleep apnea finds commercialization partner

Varun Saxena / FierceMedicalDevices

Irvine, CA's Alphaeon gained exclusive worldwide commercialization rights to Zelegent's in-office procedure to reduce snoring, as devicemakers scramble to develop new methods to combat obstructive sleep apnea.

Report suggests that to grow, India's industry must sync its standards to the West

Eric Palmer / FeircePharmaManufactoring

Scores of Indian drugmakers, including India's largest, are having to make plant improvements and change their processes after FDA regulators cited their plants for all sorts of shortcomings. And that is likely to keep happening if the Indian pharma industry, with help from the government, doesn't make some serious improvements, warns a top business group in the country.

16 December 2015

Marinus Pharmaceuticals Completes Patient Recruitment in Phase 3 Clinical Trial of Ganaxolone in Focal Onset Seizures

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced that it has completed patient recruitment for the Phase 3 clinical trial of ganaxolone, a CNS-selective GABAA modulator, in adults with drug-resistant focal onset seizures. Sites participating in this global study have completed screening patients. After establishing eight weeks of baseline seizure frequency, patients randomized in the study undergo a two-week titration period followed by a twelve-week maintenance period. 

16 December 2015

Clinical Data from ReVision Optics’ Raindrop Near Vision Inlay Featured in Two Presentations at the OIS@AAO Conference

ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces that clinical data from its Raindrop® Near Vision Inlay for the treatment of presbyopia was the subject of two presentations at the 2015 OIS@AAO conference, held last month in Las Vegas.

As trade pacts sprout in Asia, medical device firms need to take note

EJ Lane / FeircePharmaAsia

Medical device companies should pay close attention as the mechanics grind along of getting a dozen countries to formally put the Trans-Pacific Partnership (TPP) trade pact into practice.

What can Gilead, Biogen and Celgene teach Big Pharma about R&D?

John Carroll / FierceBiotech

For the past 5 years the biopharma experts at Deloitte have been keeping an eye on a disturbing trend that shows no sign of letting up anytime soon. The biggest players in pharma have been seeing a steady erosion in their return on investment from research; peak sales estimates for what they're spending more on are plunging as the cost of commercialization is rising.